Torben Plesner

15.2k total citations · 2 hit papers
169 papers, 5.6k citations indexed

About

Torben Plesner is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, Torben Plesner has authored 169 papers receiving a total of 5.6k indexed citations (citations by other indexed papers that have themselves been cited), including 110 papers in Hematology, 74 papers in Oncology and 53 papers in Molecular Biology. Recurrent topics in Torben Plesner's work include Multiple Myeloma Research and Treatments (93 papers), Chronic Lymphocytic Leukemia Research (31 papers) and Peptidase Inhibition and Analysis (31 papers). Torben Plesner is often cited by papers focused on Multiple Myeloma Research and Treatments (93 papers), Chronic Lymphocytic Leukemia Research (31 papers) and Peptidase Inhibition and Analysis (31 papers). Torben Plesner collaborates with scholars based in Denmark, United States and Netherlands. Torben Plesner's co-authors include Henk M. Lokhorst, Niels W.C.J. van de Donk, Jean‐Marie Delaissé, Tahamtan Ahmadi, A. Kate Sasser, Jakub Krejcik, Michael Ploug, Thomas Levin Andersen, Paul G. Richardson and Keld Danø and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Torben Plesner

163 papers receiving 5.4k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma

2016 649 citations Jakub Krejcik, Inger S. Nijhof et al. Blood profile →
Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma

2016 303 citations Saad Z. Usmani, Brendan M. Weiss et al. Blood profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Torben Plesner	3.2k	2.4k	2.2k	1.4k	905	169	5.6k
Robert Vescio	2.9k 0.9×	3.0k 1.3×	3.0k 1.4×	878 0.6×	591 0.7×	150	6.0k
Jean‐François Rossi	3.2k 1.0×	2.9k 1.2×	2.7k 1.3×	1.5k 1.1×	693 0.8×	110	6.4k
Joseph O. Moore	3.3k 1.0×	1.9k 0.8×	1.8k 0.8×	962 0.7×	1.5k 1.6×	148	6.6k
John P. Chute	1.9k 0.6×	1.5k 0.6×	2.0k 0.9×	1.0k 0.8×	865 1.0×	135	5.0k
Ulrich Jäger	2.4k 0.8×	1.7k 0.7×	1.8k 0.8×	1.2k 0.8×	1.2k 1.3×	172	5.7k
Suzanne Lentzsch	4.9k 1.6×	3.4k 1.4×	4.5k 2.1×	830 0.6×	920 1.0×	227	7.2k
Martin Gramatzki	1.8k 0.6×	2.5k 1.1×	2.1k 1.0×	2.6k 2.0×	844 0.9×	207	6.8k
David Avigan	2.6k 0.8×	2.9k 1.2×	3.0k 1.4×	3.7k 2.7×	410 0.5×	208	7.5k
Guy Pratt	1.9k 0.6×	1.8k 0.7×	2.4k 1.1×	1.2k 0.9×	1.5k 1.7×	184	5.3k
David A. Rizzieri	4.3k 1.4×	2.5k 1.0×	3.0k 1.4×	1.6k 1.2×	1.6k 1.8×	309	8.1k

Countries citing papers authored by Torben Plesner

Since Specialization

Citations

This map shows the geographic impact of Torben Plesner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Torben Plesner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Torben Plesner more than expected).

Fields of papers citing papers by Torben Plesner

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Torben Plesner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Torben Plesner. The network helps show where Torben Plesner may publish in the future.

Co-authorship network of co-authors of Torben Plesner

This figure shows the co-authorship network connecting the top 25 collaborators of Torben Plesner. A scholar is included among the top collaborators of Torben Plesner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Torben Plesner. Torben Plesner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Belch, Andrew, Torben Plesner, Paul G. Richardson, et al.. (2024). Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma. Carolina Digital Repository (University of North Carolina at Chapel Hill).

Plesner, Torben, Simon J. Harrison, Hang Quach, et al.. (2023). Phase I Study of Safety and Pharmacokinetics of RO7297089, an Anti-BCMA/CD16a Bispecific Antibody, in Patients with Relapsed, Refractory Multiple Myeloma. SHILAP Revista de lepidopterología. 5(1). 43–51. 16 indexed citations

Thorsen, Jonathan, Charlotte T. Hansen, Mikael Frederiksen, et al.. (2020). Clinically‐suspected cast nephropathy: A retrospective, national, real‐world study. American Journal of Hematology. 95(11). 1352–1360. 10 indexed citations

Miguel, Jesús F. San, Saad Z. Usmani, María‐Victoria Mateos, et al.. (2020). Subcutaneous daratumumab in patients with relapsed or refractory multiple myeloma: Part 2 of the open-label, multicenter, dose-escalation phase 1b study (PAVO). Haematologica. 106(6). 1725–1732. 25 indexed citations

Möller, Sören, et al.. (2019). The Clinical Course of Multiple Myeloma in the Era of Novel Agents: A Retrospective, Single-Center, Real-World Study. SHILAP Revista de lepidopterología. 1(4). 220–228. 13 indexed citations

Krejcik, Jakub, Inger S. Nijhof, Berris van Kessel, et al.. (2017). Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab. Clinical Cancer Research. 23(24). 7498–7511. 119 indexed citations

Donk, Niels W.C.J. van de, Antonio Palumbo, Hans Erik Johnsen, et al.. (2014). The clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders: recommendations from the European Myeloma Network. Haematologica. 99(6). 984–996. 107 indexed citations

Heeg, Bart, Michel van Agthoven, Johan Liwing, et al.. (2014). Treatment Sequencing Survival Model for Patients with Multiple Myeloma Ineligible for Stem Cell Transplantation (SCT). Value in Health. 17(7). A617–A618. 2 indexed citations

Gudbrandsdottir, Sif, Henrik Birgens, Henrik Frederiksen, et al.. (2013). Rituximab and dexamethasone vs dexamethasone monotherapy in newly diagnosed patients with primary immune thrombocytopenia. Blood. 121(11). 1976–1981. 125 indexed citations

10.

Birgens, Henrik, Henrik Frederiksen, Hans Carl Hasselbalch, et al.. (2013). A phase III randomized trial comparing glucocorticoid monotherapy versus glucocorticoid and rituximab in patients with autoimmune haemolytic anaemia. British Journal of Haematology. 163(3). 393–399. 112 indexed citations

11.

Søe, Kent, et al.. (2013). Is retention of zoledronic acid onto bone different in multiple myeloma and breast cancer patients with bone metastasis?. Journal of Bone and Mineral Research. 28(8). 1738–1750. 6 indexed citations

12.

Lund, Thomas, Niels Abildgaard, Thomas Levin Andersen, Jean‐Marie Delaissé, & Torben Plesner. (2010). Multiple myeloma: changes in serum C‐terminal telopeptide of collagen type I and bone‐specific alkaline phosphatase can be used in daily practice to detect imminent osteolysis*. European Journal Of Haematology. 84(5). 412–420. 22 indexed citations

13.

Lund, Thomas, Kent Søe, Niels Abildgaard, et al.. (2010). First‐line treatment with bortezomib rapidly stimulates both osteoblast activity and bone matrix deposition in patients with multiple myeloma, and stimulates osteoblast proliferation and differentiation in vitro. European Journal Of Haematology. 85(4). 290–299. 36 indexed citations

14.

Christensen, Jacob Haaber, et al.. (2007). Interphase fluorescence in situ hybridization in multiple myeloma and monoclonal gammopathy of undetermined significance without and with positive plasma cell identification: analysis of 192 cases from the Region of Southern Denmark. Cancer Genetics and Cytogenetics. 174(2). 89–99. 23 indexed citations

15.

Hagenbeek, Anton, et al.. (2005). A novel fully human anti-CD20 monoclonal antibody: First clinical results from an ongoing phase I/II trial in patients with follicular non-Hodgkin's lymphoma. Annals of Oncology. 16. 71–71. 3 indexed citations

16.

Boissy, Patrice, Thomas Levin Andersen, Basem M. Abdallah, et al.. (2005). Resveratrol Inhibits Myeloma Cell Growth, Prevents Osteoclast Formation, and Promotes Osteoblast Differentiation. Cancer Research. 65(21). 9943–9952. 167 indexed citations

17.

Nielsen, Dorte, Jens Eriksen, Christian Maare, et al.. (2000). Characterisation of Non-P-Glycoprotein multidrug-resistant Ehrlich ascites tumour cells selected for resistance to mitoxantrone. Biochemical Pharmacology. 60(3). 363–370. 9 indexed citations

18.

Geisler, Carsten, Jan Dominik Kuhlmann, Thomas Möller, Torben Plesner, & Bent Rubin. (1990). Transmembrane Signalling via HLA‐DR Molecules on T Cells from a Sezary T‐Cell Leukaemia Line. Scandinavian Journal of Immunology. 32(6). 731–735. 9 indexed citations

19.

Geisler, Carsten, JK Larsen, & Torben Plesner. (1988). Identification of αβ and γδ T Cell Receptor‐Positive Cells. Scandinavian Journal of Immunology. 28(6). 741–745. 3 indexed citations

20.

Stein, Harald, et al.. (1984). In situ immunological characterization of Langerhans cells with monoclonal antibodies: Comparison with other dendritic cells in skin and lymph nodes. Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin. 403(4). 401–412. 44 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact